(1) Medical Center Clinical Institute for Reproductive Medicine, Pleven, Bulgaria
(2) Department of Dermatology and Venereology, UMHAT “Dr. Georgi Stranski”, Medical University, Pleven, Bulgaria
ABSTRACT — OBJECTIVE: Human papillomavirus (HPV) persistent infections of genital tract are strongly related to the development of genital warts and cellular transformation. These infections lead to different type of anogenital cancers, including cervical, vulvar and vaginal.
Current therapeutic treatments of genital warts include surgical removal, physician-applied and patient-applied treatments. Most of these treatments aim to remove the wart, with low effect on virus infectivity. Therefore, recurrence rate represents a significant issue that has not been yet addressed. Moreover, adverse events and patient discomfort hamper the potential of these treatments. The aim of our study was to present a protocol proposal for the treatment of primary and recurrent genital warts based on Coriolus-MRL and polyhexamethylene biguanide application (PHMB).
PATIENTS AND METHODS: 42 Patients with primary (15 patients) and recurrent (27 patients) genital warts were treated with the immunostimulator Coriolus-MRL and PHMB solution. Coriolus-MRL (Mycology Research Laboratories Ltd, Luton, Bedfordshire, United Kingdom) was administered as 2 tablets, 3 times per day, for six months while PHMB-gynaecological solution, a mono-dose gynaecological liquid-gel, was prepared and self-administered by patients before bedtime, every four days for twenty days and, afterward, every twenty days for the following six months. The control group was treated only with Coriolus-MRL, 2 tablets, 3 times per day, for six months. All patients with recurrent genital warts were previously treated with podophyllin local therapy.
CONCLUSIONS: These results have demonstrated that combined therapy with Coriolus-MRL and PHMB solution provide positive outcomes in cases of primary or recurrent genital warts.
Link to article:
https://www.ijmdat.com/article/220
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Full Article
Clinical articles
-
Mushroom Nutrition In Neurodegenerative Diseases
Prof. Vittorio Calabrese
Faculty of Medicine, University of Catania and University of Messina, Italy -
Targeting Neurogenesis with Mushroom Nutrition: A Mini Review
Dr. Elisabete Ferreiro, CNC-Center for Neuroscience and Cell Biology
CIBB-Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Prof. Tito Fernandes, CIISA
Faculty of Veterinary Medicine, Lisbon University, Lisbon, Portugal -
Central Nervous System Profiling of Hericium erinaceus Biomass Powder by an Electropharmacogram Using Spectral Field Power in Conscious Freely Moving Rats
Prof. Wilfried Dimpfel Justus
Liebig-University Giessen, Germany
Dr. Julie Wiebe
Nektium Pharm S.L., Las Palmas, Spain
Dr. Nigel Gericke, Gericke Consulting
Baden, Switzerland
-
A TCM Perspective on Mushroom Nutrition: Hericium erinaceus and Trametes versicolor (synn. Coriolus versicolor) as a synergistic combination
Karel Simonovsky and Zuzana Vancurikova